Clinical stage biopharmaceutical company Catabasis Pharmaceuticicals Inc. has pulled in an $8.7 million round of funding, according to federal documents.
This is the not the first investment round for the Cambridge, Mass-based company which is focused on the development of treatments for metabolic and inflammatory diseases. In 2010, the company closed a $48 million Series A financing backed by SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures. In December 2011, the company received an $8 million Series A extension.